Brief: Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease
17/04/2025 12:29
April 17 (Reuters) - Uniqure NV UQ1.F: UNIQURE ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO AMT-130 FOR THE TREATMENT OF HUNTINGTON’S DISEASE UNIQURE NV: ADDITIONAL REGULATORY UPDATE & GUIDANCE ON BIOLOGICS LICENSE APPLICATION SUBMISSION EXPECTED IN Q2 2025 Source text: ID:nGNX2NsVHq Further company coverage: UQ1.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal